Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression
Shenaz Khan, … , Jorge Calles, Jeffrey R. Schelling
Shenaz Khan, … , Jorge Calles, Jeffrey R. Schelling
Published July 2, 2020
Citation Information: JCI Insight. 2020;5(15):e136845. https://doi.org/10.1172/jci.insight.136845.
View: Text | PDF
Research Article Metabolism Nephrology

Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression

  • Text
  • PDF
Abstract

Kidney disease is one of the most devastating complications of diabetes, and tubular atrophy predicts diabetic kidney disease (DKD) progression to end-stage renal disease. We have proposed that fatty acids bound to albumin contribute to tubular atrophy by inducing lipotoxicity, after filtration across damaged glomeruli, and subsequent proximal tubule reabsorption by a fatty acid transport protein-2–dependent (FATP2-dependent) mechanism. To address this possibility, genetic (Leprdb/db eNOS–/–) and induced (high-fat diet plus low-dose streptozotocin) mouse models of obesity and DKD were bred with global FATP2 gene–deleted mice (Slc27a2) and then phenotyped. DKD-prone mice with the Slc27a2–/– genotype demonstrated normalization of glomerular filtration rate, reduced albuminuria, improved kidney histopathology, and longer life span compared with diabetic Slc27a2+/+ mice. Genetic and induced DKD-prone Slc27a2–/– mice also exhibited markedly reduced fasting plasma glucose, with mean values approaching euglycemia, despite increased obesity and decreased physical activity. Glucose lowering in DKD-prone Slc27a2–/– mice was accompanied by β cell hyperplasia and sustained insulin secretion. Together, our data indicate that FATP2 regulates DKD pathogenesis by a combined lipotoxicity and glucotoxicity (glucolipotoxicity) mechanism.

Authors

Shenaz Khan, Robert Gaivin, Caroline Abramovich, Michael Boylan, Jorge Calles, Jeffrey R. Schelling

×

Figure 8

Plasma insulin levels are preserved in mice with FATP2 gene deletion.

Options: View larger image (or click on image) Download as PowerPoint
Plasma insulin levels are preserved in mice with FATP2 gene deletion.
(A...
(A) Plasma insulin was measured by ELISA, as described in Methods, in DKD mice with or without FATP2 gene deletion. *P = 0.001 by unpaired t test. (B) Relationship between plasma glucose and corresponding insulin concentrations. R2 = 0.682, P = 0.0009 by linear regression and Pearson’s correlation. (C) Effect of FATP2 gene deletion on mean plasma insulin concentration over time. n = 4–6 samples per group per time point. Error bars were omitted for clarity. *P < 0.02 compared with other groups by ANOVA and Tukey’s test for multiple comparisons. (D) Insulin levels in 6-month-old WT and Slc27a2–/– mice treated with or without HFD with or without low-dose STZ. *P < 0.05 compared with other groups by ANOVA and Tukey’s test for multiple comparisons. FATP2, fatty acid transport protein-2; DKD, diabetic kidney disease; STZ, streptozotocin.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts